Mechanism behind deadly fungal infection on top of influenza or Covid-19 deciphered
Over 15 per cent of all critically ill patients who end up in intensive care with severe influenza or Covid-19 additionally develop aspergillosis, a pulmonary fungal infection. This doubles their mortality rate. A UZ Leuven and KU Leuven trial with international partners has revealed that multiple dysfunctions of the immune response lie at the basis of higher susceptibility to fungal infections. These insights were published in The Lancet Respiratory Medicine and constitute an important first step towards increasing the survival rate of patients with these severe lung infections.
Every year, hundreds of thousands of people worldwide end up in intensive care with influenza or Covid-19. About 15 per cent of them develop an additional lung infection with the common fungus Aspergillus (aspergillosis). In healthy people, this infection hardly ever leads to illness. For critically ill patients with an underlying influenza or Covid-19 infection, however, aspergillosis can be deadly: the fungus can start to grow in the tissue of their respiratory tract and lungs and cause irreversible damage. The mortality rate of these patients becomes 40%-50%, about twice as high as that of ICU patients who only have severe influenza or Covid-19.
Compromised immune system
To find out why some patients with severe influenza or Covid-19 also develop aspergillosis and what to do about it, UZ Leuven and KU Leuven researchers set up an observational study, together with international colleagues. The study uncovered part of the mechanism that opens the door to an additional fungal infection in patients with an influenza or coronavirus infection.
Prof. dr. Joost Wauters (UZ Leuven/KU Leuven), intensivist at UZ Leuven and the principal investigator of the study, explained: “We discovered that, in patients with serious influenza or Covid-19 who develop this type of fungal infection, the innate immune system had been affected in various areas. Their immune cells, which in healthy people are responsible for eliminating fungal spores in the lungs, were compromised. Furthermore, the white blood cells that would normally clean up fungal hyphae did not seem to function properly in those influenza or Covid-19 patients. It was surprising to see that partly similar deviating immune processes come into play in both Covid-19 and influenza.”
Dr. Simon Feys, internist in training at UZ Leuven and doctoral researcher at KU Leuven, added: “In tissue stainings, we also saw that the corona or influenza virus affects the epithelium of the lungs. This is the layer of cells that lines the respiratory tract and lung tissue, which forms the first barrier against infections. For Covid-19, we were able to show that specifically in the locations where the virus affects the epithelium, the fungus also penetrates the tissue.”
Therapeutic target
Johan Van Weyenbergh (KU Leuven Rega Institute), PhD, who is the co-lead of the study, said: “With this information, we can develop biomarkers that help to predict which patients are more susceptible to a fungal infection and therefore need close follow-up.”
Professor Agostinho Carvalho (University of Braga, Portugal), who also co-lead the study, added: “Our results also lead the way for further research into medication that can repair the affected processes of the immune system and, as a result, suppress the fungal infection.
More about the study
The study was performed using lung samples of 169 patients with influenza or Covid-19, with or without aspergillosis. Most of the samples were collected over the last couple of years via bronchoalveolar lavage, a classical diagnostic technique for suspected lung infections, and stored in the Leuven biobank.
In 2018, Professor Joost Wauters and his team were the first to report the dangerous combination of aspergillosis and influenza, which led to worldwide vigilance in intensive care units. The current follow-up study now uncovers the mechanism, which will pave the way for the development of biomarkers and modified treatments for patients with this double infection. The corona pandemic made it interesting to include the samples of patients with Covid-19 as well as samples of patients with influenza.
The study was performed in collaboration with various research groups of KU Leuven and UZ Leuven, as well as researchers from ZNA (Belgium), the University of Braga (Portugal), the Max Planck Research Unit for Neurogenetics in Frankfurt (Germany), CHU Amiens-Picardie (France) and the Radboud Universiteit in Nijmegen (The Netherlands). The study was part of the Horizon 2020 HDM-FUN project.
Read the published article in the leading medical journal The Lancet Respiratory Medicine.
Related News
ArtiQ joins forces with Clario in strategic acquisition deal to transform respiratory solutions
Leuven models help unlock the dark part of space in the largest European Space Agency mission ever
QbD Chair for Precision Oncology Research in Glioblastoma extended for three years
Zeopore is making its mark in emerging green applications through catalyst optimization leadership
Leuven-based hydrogen panels become an official KU Leuven spin-off
Leuven's imec research centre targets 1950 new hires by 2035
Materialise plays crucial role in world's first-ever eye transplant
KU Leuven students win the world championships for solar cars!
Leuven-based VirusBank Platform enhances society's preparedness against future viral epidemics and pandemics
Leuven's Centre for Drug Design and Discovery (CD3) raises € 70.5 Million
International School in Leuven opens new school building for children of expats
Qaelum NV Partners with I-MED Radiology Network to Enhance Patient Dose Analysis and Incident Reporting in the ANZ Region
How can we help?
The Leuven MindGate team is at your disposal for any questions about the Leuven Innovation Region. Do you want to invest, work or study in the region? We can help you find your way.
We also facilitate collaboration and innovation between companies, knowledge institutes and government within the Leuven Innovation Region, and we are happy to guide any of these stakeholders towards innovation.